TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) had its price target lowered by HC Wainwright from $14.00 to $13.00 in a research note published on Monday morning, The Fly reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for TCR2 Therapeutics’ Q4 2022 earnings at ($0.82) EPS, FY2022 earnings at ($3.19) EPS, Q1 2023 earnings at ($0.84) EPS, Q2 2023 earnings at ($0.87) EPS, Q3 2023 earnings at ($0.89) EPS, Q4 2023 earnings at ($0.91) EPS and FY2023 earnings at ($3.51) EPS.
TCRR has been the topic of several other reports. Piper Sandler dropped their price objective on shares of TCR2 Therapeutics from $16.00 to $8.00 in a research report on Tuesday, November 8th. Truist Financial lowered their price target on shares of TCR2 Therapeutics to $18.00 in a research report on Tuesday, August 23rd. Finally, Roth Capital reaffirmed a buy rating on shares of TCR2 Therapeutics in a research report on Monday, August 8th.
TCR2 Therapeutics Price Performance
Shares of TCRR opened at $1.27 on Monday. The firm has a market capitalization of $49.10 million, a PE ratio of -0.41 and a beta of 1.77. The company’s 50-day moving average is $1.60 and its 200-day moving average is $2.41. TCR2 Therapeutics has a fifty-two week low of $1.23 and a fifty-two week high of $5.65.
Institutional Investors Weigh In On TCR2 Therapeutics
TCR2 Therapeutics Company Profile
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
- Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.